Eicosanoids constitute a large family of biologically active lipid mediators that are produced by two enzyme classes, cyclooxygenases (COX-1 and COX-2) and lipoxygenases (5-LO, 12-LO, and 15-LO). Increasing evidence suggests that in addition to a variety of epithelial malignancies, the two most common types of human brain tumour, gliomas and meningiomas, aberrantly overexpress eicosanoid producing enzymes and release a spectrum of eicosanoids that may promote tumorigenesis and the development of peritumorous brain oedema. Glioma and meningioma cells are killed in vitro and in animal models when exposed to COX-2 and 5-LO inhibitors, and their effectiveness is under investigation in clinical trials for treatment of patients with malignant brain tumours. However, despite research into the role of the eicosanoid cascade in the tumorigenesis of human brain tumours, many important questions remain unanswered. Current and newer agents that specifically target key players of the eicosanoid cascade could change the approach to treating brain tumours, because their benefits may lie in their synergism with conventional cytotoxic treatments and/or with other novel agents targeted against other procarcinogenic pathways.

Primary brain tumours are among the top 10 causes of cancer related death. Approximately 13,000 people die from these tumours each year in the USA. Gliomas and other neuroepithelial tumours make up 49% of primary brain tumours, and meningiomas are the second most common primary brain tumour (27%).

The World Health Organisation (WHO) classifies gliomas as astrocytomas, oligodendrogliomas, and oligoastrocytomas on the basis of the phenotypical resemblance of tumour cells to normal glia (astrocytes or oligodendrocytes, or a combination of both). Astrocytomas are histologically graded as low grade (WHO I and II) and high grade tumours that are classified as anaplastic astrocytoma (WHO III) and glioblastoma multiforme (GBM) (WHO IV), respectively. The infiltrative growth pattern of high grade gliomas precludes them from being cured by neurosurgery and they respond poorly to other forms of treatment. The median survival of patients with a newly diagnosed GBM has improved only marginally during the past two decades, and today most patients with GBM still die from their disease in less than a year. In contrast, meningiomas are usually benign tumours that develop from the leptomeningeal cells of the arachnoid membrane that surrounds the brain and spinal cord. However, they often recur after seemingly complete surgical removal and occasionally progress to a fully malignant phenotype. Moreover, surgical cure is often not possible in those meningiomas involving the skull base or vital neurovascular structures.

In the past two decades, a large number of molecular and genetic pathways that are altered in brain tumour cells have been identified. However, the development of novel treatment strategies based on this molecular information has not yet been successfully translated to common clinical practice. A variety of promising drugs that selectively target precise molecular abnormalities, which create and drive the neoplastic phenotype of glioma and meningioma cells, are currently being investigated in clinical trials to improve the survival and quality of life of patients with brain tumours.

In this review, we will discuss the eicosanoid cascade of arachidonic acid (AA) and its relevance to brain tumours, the current evidence for the rationale of using inhibitors of eicosanoid producing enzymes for therapeutic purposes, and the limitations that hinder the full implementation of this form of treatment; in addition, we will suggest future directions for research and clinical practice.

**INCREASED CONCENTRATIONS OF AA IN BRAIN TUMOURS**

AA is a ω-6 polyunsaturated fatty acid (PUFA) that is converted into biologically active lipid compounds called eicosanoids. Eicosanoids constitute a large family of biologically active lipid mediators that are produced by two enzyme classes, cyclooxygenases (COX-1 and COX-2) and lipoxygenases (5-LO, 12-LO, and 15-LO).

**Abbreviations:** AA, arachidonic acid; COX, cyclooxygenase; GBM, glioblastoma multiforme; LA, linoleic acid; LO, lipoxygenase; PG, prostaglandin; PLA, phospholipase; PUFA, polyunsaturated fatty acid; WHO, World Health Organisation

See end of article for authors’ affiliations

Correspondence to:
Dr N Nathoo, Department of Neurosurgery, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, 44195, Ohio, USA; nathoon@ccf.org

Accepted for publication 20 August 2003

References

1. The World Health Organisation (WHO) classifies gliomas as astrocytomas, oligodendrogliomas, and oligoastrocytomas on the basis of the phenotypical resemblance of tumour cells to normal glia (astrocytes or oligodendrocytes, or a combination of both). Astrocytomas are histologically graded as low grade (WHO I and II) and high grade tumours that are classified as anaplastic astrocytoma (WHO III) and glioblastoma multiforme (GBM) (WHO IV), respectively.

2. The infiltrative growth pattern of high grade gliomas precludes them from being cured by neurosurgery and they respond poorly to other forms of treatment. The median survival of patients with a newly diagnosed GBM has improved only marginally during the past two decades, and today most patients with GBM still die from their disease in less than a year.

3. In contrast, meningiomas are usually benign tumours that develop from the leptomeningeal cells of the arachnoid membrane that surrounds the brain and spinal cord. However, they often recur after seemingly complete surgical removal and occasionally progress to a fully malignant phenotype.

4. Moreover, surgical cure is often not possible in those meningiomas involving the skull base or vital neurovascular structures.

5. In this review, we will discuss the eicosanoid cascade of arachidonic acid (AA) and its relevance to brain tumours, the current evidence for the rationale of using inhibitors of eicosanoid producing enzymes for therapeutic purposes, and the limitations that hinder the full implementation of this form of treatment; in addition, we will suggest future directions for research and clinical practice.

6. AA is a ω-6 polyunsaturated fatty acid (PUFA) that is converted into biologically active lipid compounds called eicosanoids. Eicosanoids constitute a large family of biologically active lipid mediators that are produced by two enzyme classes, cyclooxygenases (COX-1 and COX-2) and lipoxygenases (5-LO, 12-LO, and 15-LO).

7. The World Health Organisation (WHO) classifies gliomas as astrocytomas, oligodendrogliomas, and oligoastrocytomas on the basis of the phenotypical resemblance of tumour cells to normal glia (astrocytes or oligodendrocytes, or a combination of both). Astrocytomas are histologically graded as low grade (WHO I and II) and high grade tumours that are classified as anaplastic astrocytoma (WHO III) and glioblastoma multiforme (GBM) (WHO IV), respectively.
These lipid compounds modulate diverse physiological and pathological processes including carcinogenesis. Several eicosanoids have been shown to promote cell survival, and modulate cell adhesion and motility. Lipoxygenases (LOs) introduce one molecule of oxygen into AA metabolites eicosanoids. The insertion of a single oxygen atom into AA by certain cytochrome P-450 enzymes produces epoxy-AAs. Cyclooxygenases (COXs) introduce two molecules of oxygen into AA, and prostaglandins, thromboxanes, prostacyclin, and lipoxins are produced as COX-1 and COX-2 derived eicosanoids. The causes and molecular mechanisms leading to the raised concentrations of LA and AA in gliomas and meningiomas are presently unknown. LA is an essential fatty acid that humans are unable to biosynthesise and is obtained exclusively through dietary intake. Therefore, it is possible that raised concentrations of LA and AA in brain tumours may be related to high dietary consumption. Even though dietary LA (abundant in oils from various seeds) is the precursor of AA in tissues, dietary AA (exclusive to foods of animal origin) is perhaps the single most important nutritional determinant regulating AA values in humans.

Epidemiological studies on dietary fat intake and the risk of brain tumours are sparse and not consistent. Giles et al reported an increased risk of glioma in adult Australians with a high intake of oils, margarine, and salad dressing. Lubin et al reported that children with brain tumours had a higher consumption of vegetable fat than did controls. However, no significant association between the risk of glioma and intake of dietary fat was reported in a recent study from...
Nebraska, whereas increased consumption of total fat and cholesterol was found to be inversely associated with glioma risk in Israel.

Even if people who develop gliomas and meningiomas do not have a higher intake of AA and LA, it is possible that molecular changes in these tumours may lead to more efficient accumulation of these PUFAs in the tumour tissue in the presence of a normal dietary intake. For example, increased expression of fatty acid-CoA ligase 4, an enzyme that uses AA preferentially as a substrate for esterification into membrane phospholipids, was found in adenocarcinomas of the colon compared with normal tissue. However, it remains to be determined whether similar molecular changes occur in brain tumours. Another reason why brain tumours contain raised concentrations of PUFAs may be that these tumours do not contain enzymes that would oxidise AA into eicosanoids. However, as described below, a large body of evidence does not support such an idea.

"Phospholipase A₂ is the key enzyme involved in the initiation of the entire eicosanoid cascade because it releases free arachidonic acid from the sn-2 position of membrane phospholipids."

Although ω-6 fatty acids are abundant in the membrane phospholipids of brain tumour cells, only free unesterified fatty acids that are released from the membrane phospholipids can be metabolised into eicosanoids. Intracellular concentrations of free AA are low, so that its formation limits the synthesis of eicosanoids. Phospholipase A₂ (PLA₂) is the key enzyme involved in the initiation of the entire eicosanoid cascade because it releases free AA from the sn-2 position of membrane phospholipids. Although mammalian cells normally contain more than 12 members of the PLA₂ group of enzymes, very limited information exists about PLA₂ enzymes in human brain tumours. The expression and enzymatic activity of the calcium sensitive cytosolic PLA₂ has been reported in normal human astrocytes, human astrocytoma cell lines 1321N1 and UC-11 MG, but not in U-373 MG cells. Low amounts of the secreted form of PLA₂ and low enzymic activity were detected in normal rat astrocyte cell cultures and were dramatically induced by proinflammatory stimuli such as tumour necrosis factor α. To our knowledge, the expression of other types of PLA₂ enzymes has not been reported in gliomas and meningiomas. Inhibition of PLA₂ by non-specific PLA₂ agents (4-bromophenacylbromide and quinacrine) suppressed the proliferation of primary meningioma cell cultures and the established human astrocytoma cell line, U373 MG, and these effects were partially reversed by the addition of exogenous AA. These findings suggest that PLA₂ activity may be important for glioma and meningioma cell proliferation.

**INCREASED EXPRESSION OF EICOSANOID PRODUCING ENZYMES IN GBM AND MENINGIOMA Ciclooxgenase**

The crucial role of COX eicosanoids has been clearly demonstrated in human colon cancer, in which COX-2 is often overexpressed. COX inhibitors, such as non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors, can reduce the incidence of colorectal cancer in humans and experimental animals, and can decrease the polyp number and size in patients with familial adenomatous polyposis. In addition to colon cancer, COX-2 is overexpressed in a spectrum of human malignancies, such as cancer of the breast, prostate, pancreas, oesophagus, skin and lung. Recently, gliomas and meningiomas were also found to overexpress both COX and lipoxygenase enzymes compared with normal brain tissue. Overexpression of both COX-1 and COX-2 enzymes was recently documented in human gliomas. In astrocytic gliomas, COX-1 was predominantly expressed in macrophages/microglial cells of the tumour mass, whereas COX-2 expression was mostly found in tumour cells and in single macrophages/microglial cells in perinecrotic areas. COX-2 expression was shown to correlate with the pathological grade and proliferation rate of gliomas. However, Matsuo et al reported that the staining intensity of GBM was relatively weak, but that astrocytomas (grades II and III) and meningiomas were strongly positive for COX-2. Shono et al found that patients with glioma who had the highest expression of COX-2 had the shortest survival. COX-2 was identified as the strongest predictor of outcome, independent of all other variables examined.

A differential accumulation of COX isoforms during oligodendroglial tumour progression has also been recorded, with higher COX-1 expression in tumour cells of those patients whose tumours have “upgraded” to a more malignant phenotype. Both survival and the time to tumour progression were longer in those patients with a low COX-1 labelling score compared with patients whose tumours displayed high COX-1 expression. Oligodendroglial tumours, in particular the anaplastic variant that recurred, expressed a higher number of COX-2 positive cells (mostly neurones and astrocytes) than did healthy control brains. Oligodendroglioma COX-2 protein expression was also examined in our laboratories by Castilla et al. In this study, the predominant COX-2 staining was not attributable to macrophages/microglial cells or reactive astrocytes but rather to tumour cells. In addition, COX-2 immunoreactivity was associated with decreased patient survival, along with retention of chromosome 1p and a high MIB-1 labelling index, whereas negative immunoreactivity for COX-2 and allelic loss of chromosome 1p correlated with better survival.

**5-Lipoxygenase**

Although much attention has been focused on the role of COX derived metabolites in cancer development and progression, accumulating evidence suggests that 5-LO derived eicosanoids may play equally important roles. 5-LO mRNA and/or protein was found to be overexpressed in human lung, prostate, pancreatic and colon cancers. Boado et al reported increased expression of 5-LO mRNA in three of three GBM and three of three meningioma surgical specimens examined. The increase in 5-LO mRNA was greater in the GBM samples than in the meningiomas. Recent work from our laboratory suggested that surgical specimens of high grade astrocytomas and meningiomas overexpress 5-LO. Immunohistochemical analysis of surgical astrocytoma specimens shows that tumour cells and infiltrating macrophages/microglial cells express high amounts of 5-LO protein. In contrast, little if any 5-LO staining is detected in non-tumorous white matter control tissue. In addition, high amounts of both 5-LO mRNA and protein were expressed in some established GBM cell lines and a primary GBM cell culture. Staining for 5-LO was significantly more frequent in high grade than in low grade tumours (N Nathoo et al, unpublished data).

"Recent work from our laboratory suggested that surgical specimens of high grade astrocytomas and meningiomas overexpress 5-lipoxygenase"

We also detected high expression of 5-LO in primary meningioma cells and meningioma surgical specimens by
ENHANCED PRODUCTION OF EICOSANOIDs IN GLIOmAS AND MENINGIOMAS

The existence of high concentrations of COX and 5-LO enzymes and their substrate (AA) in glioma and meningioma cells creates a favourable environment for the efficient production of eicosanoids. Therefore, it is not surprising that cultured meningioma and glioma cells produce high amounts of prostaglandins, thromboxanes, and leukotrienes compared with normal brain tissue. AA metabolism capacity correlated well with proliferation patterns in neuroepithelial tumours, and was shown to be related to steroid receptors in certain brain tumours; that is, some metabolites of AA were produced in different amounts in brain tumours, which either did or did not express steroid receptors.

In addition to in vitro production, eicosanoids can be detected systemically in patients with brain tumours, and their concentrations have been reported to decrease following neurosurgical resection or after treatment with specific inhibitors. In a recent clinical study, patients with malignant brain tumours (GBM, anaplastic astrocytoma, malignant meningioma, and medulloblastoma) had significantly higher concentrations of prostaglandin E2 (PGE2) in their plasma than did patients with benign brain tumours (meningiomas and pituitary adenomas), metastatic brain tumours or normal control patients. The high concentrations of PGE2 decreased significantly (by a factor of three) three days after surgical removal of both malignant and benign brain tumours. Simmet et al detected high concentrations of leukotriene E4 in the urine of eight patients with GBM. The values dropped by 80% within seven days of surgical removal of the tumour. In contrast, five patients with meningiomas excreted less leukotriene E4 and the values did not change significantly following meningioma removal. These data suggest that malignant brain tissue is the source of raised systemic COX and 5-LO derived eicosanoids.

‘The use of cyclooxygenase 2 and 5- lipoxigenase inhibitors may even be an alternative to glucocorticoids for the treatment of eicosanoid induced peritumorous brain oedema’

Of particular importance is the observation that eicosanoids, produced by brain tumour cells, probably cause the development of tumour induced brain oedema. Peritumorous brain oedema is frequently found in both gliomas and meningiomas, and can contribute to the morbidity of patients with brain tumours. Glucocorticoids (such as dexamethasone) are used to treat peritumorous brain oedema. Although glucocorticoids often provide dramatic symptomatic relief for patients, they have many undesirable side effects.

Of particular concern is the possibility that glucocorticoids may attenuate the cytotoxic effects of chemotherapy. For example, they activate the human $\alpha^0$-methylguanine DNA methyltransferase gene. The product of this gene functions as a DNA repair protein that removes the mutagenic DNA adduct $\alpha^0$-alkylguanine, which is generated after exposure to alkylating antitumour drugs, such as those used for chemotherapy of GBM.

A substantial part of the beneficial effects of glucocorticoids in reducing oedema results from the suppression of PLA2 activity and the reduction of free AA, in addition to inhibition of COX-2. However, there are reports suggesting that glucocorticoids upregulate the expression of 5-LO in rat neurones, human monocytes, and mast cells. Although the effects of glucocorticoids on 5-LO expression in vivo are unknown, these observations may have important therapeutic applications. These findings suggest that glucocorticoids and 5-LO inhibitors would have additive clinical benefits, and the use of COX-2 and 5-LO inhibitors may even be an alternative to glucocorticoids for the treatment of eicosanoid induced peritumorous brain oedema.

EICOSANOID INHIBITORS

An additional line of evidence supporting the concept that the COX-1, COX-2, and 5-LO proteins are involved in the tumorigenesis of gliomas and meningiomas comes from studies using COX and 5-LO inhibitors. Non-selective COX inhibitors, such as acetylsalicylic acid (aspirin), indomethacin, flurbiprofen, sulindac, and piroxicam, inhibited the growth of rat glioma cells both in vitro and in vivo, and several human glioma cells in vitro.

Inhibitors of thromboxane synthase suggest a novel anti-invasive approach for the treatment of gliomas. Thromboxane synthase converts COX derived PGH2 into thromboxane A2 and it was found to be overexpressed in highly migratory subpopulations of glioma cells. Specific thromboxane synthase inhibitors, such as furegrelate and dazmegrel, inhibited glioma cell migration and induced the apoptosis of these cells. When furegrelate was combined with camptothecin, it exerted a strong synergistic effect on the induction of apoptosis in glioma cells. Thus, further elucidation of the molecular mechanisms by which eicosanoids regulate glioma invasion will probably result in new ways to alter the migration and invasion of glioma cells and/or to increase their sensitivity to chemotherapeutic agents.

Boswellia serrata, naturally occurring 5-LO inhibitors from the gum resin exudate of Boswellia serrata (frankincense), are known to kill meningioma and GBM cells in vitro by the induction of apoptosis. In a rodent glioma model, the gum resin exudate of B. serrata decreased glioma volume,
enhanced apoptosis, and more than doubled the survival time of treated rats compared with non-treated animals. The effects of frankincense derived boswellic acids were examined in two other small studies of patients with gliomas. Boeker and Winking treated 29 patients with glioma using the H15 herbal preparation containing a gum resin exudate of *B serrata* for seven days. There was no effect on tumour size, but a significant reduction of peritumorous brain oedema with a concurrent improvement of the clinical condition was recorded. Streffer et al treated 11 patients with glioma (including seven patients with GBM) and progressive peritumorous brain oedema with the H15 preparation, and saw a radiological and/or clinical response to treatment in three patients with GBM.

**CURRENT LIMITATIONS AND FUTURE PERSPECTIVES**

Investigations into the possible role of eicosanoids in the development and progression of brain tumours have progressed rapidly in the past few years. Today, specific inhibitors of eicosanoid pathways are being investigated in clinical trials of brain tumours. Nevertheless, many important questions remain unanswered.

Both benign meningiomas and GBMs contain raised amounts of AA and other ω-6 PUFAs, and express high amounts of COX-2 and 5-LO enzymes with active production of eicosanoids. If eicosanoids do indeed play an important role in the tumorigenesis of these tumours, it remains to be determined whether additional molecular changes in eicosanoid cascades or those unrelated to AA metabolism are responsible for such distinct biological behaviour. For example, it is not known which of the many PLA2 enzymes are expressed and functionally active in brain tumour cells. Little is known about the expression of a variety of PG and leukotriene receptors and other eicosanoid enzymes, such as 12-LO, 15-LO, and cytochrome P450 enzymes in brain tumours. This is an important gap in our current knowledge because several specific prostaglandin and leukotriene receptor antagonists are presently available for non-tumour related clinical use. In addition, although the 12-LO pathway may be an important procarcinogenic cell regulator, 15-LO eicosanoids probably mediate the anticarcinogenic effects of PUFAs. The reasons for the existence of an unbalanced profile of fatty acids in brain tumour cells (accumulation of ω-6 and reduced amounts of ω-3 PUFAs) needs to be further elucidated. If dietary fatty acid intake is responsible, restoration of the equilibrium by dietary means in patients with brain tumours should be investigated.

Dietary fatty acids were shown to increase the expression of eicosanoid producing enzymes, such as COX-2, but they may modulate the growth and survival of brain tumour cells without their oxidation into eicosanoids. A family of steroid hormone receptors, peroxisome proliferator activated receptors, are activated not only by fatty acid metabolites but by dietary fatty acids themselves, and thus may provide a missing link between dietary fatty acids and cancer. Peroxisome proliferator activated receptor modulators are currently available for non-tumour related clinical use and are likely to stimulate investigations by brain tumour researchers in this rapidly growing field.

The tumour suppressive effects of COX and LO inhibitors may not only be related to the reduction in the production of eicosanoids, but they may also increase cellular concentrations of unesterified AA and induce the apoptosis of cancer cells. In other words, aberrantly raised expression of eicosanoid producing enzymes in tumour cells may promote tumorigenesis by increasing the intracellular utilisation of AA, thus suppressing unesterified AA mediated apoptosis. There is increasing evidence that polyunsaturated fatty acids, such as γ linolenic, arachidonic, and eicosapentaenoic acids induce cell death and apoptosis of a variety of human cancer cell lines, including glioma cells, but not “normal” non-tumorigenic cells. However, the effects on cancer cells may depend on the concentration of exogenously added fatty acid. For example, γ linolenic acid impaired the growth of glioma spheroids only at concentrations higher than 100μM, whereas lower concentrations stimulated tumour cell growth and invasion. The cytotoxic action of PUFAs may be mediated through lipid peroxidation and free radical generation, in addition to AA stimulated conversion of sphingomyelin to the apoptosis inducer ceramide. Intratumorous infusion of PUFAs in a rodent glioma model resulted in increased apoptosis and regression of tumour growth. Some improvements were documented in patients with malignant gliomas in whom γ linolenic acid was administered via a cerebral reservoir placed in the tumour bed or by direct intratumorous delivery. This treatment was found to be safe, but it remains to be determined whether higher concentrations of γ linolenic acid (or other PUFAs) and a longer duration of treatment alone or in combination with radiotherapy would result in better outcomes.

"Aberrantly raised expression of eicosanoid producing enzymes in tumour cells may promote tumorigenesis by increasing the intracellular utilisation of arachidonic acid (AA), thus suppressing unesterified AA mediated apoptosis."

Although the available evidence supports the idea that COX-2 and 5-LO proteins are aberrantly overexpressed and enzymatically active in gliomas and meningiomas, the data are less consistent with regard to the degree of staining and the nature of the cells that stain with specific antibodies. Previous investigators have used various antibodies, making it difficult to compare the results from different studies. Clearly, the use of specific antibodies directed against eicosanoid producing enzymes should be standardised so that the staining information can be used for clinical purposes, particularly those related to clinical trials with specific eicosanoid inhibitors. An additional concern when interpreting the COX-2 and 5-LO expression data is the possibility that upregulation of COX-2 and 5-LO in brain tumours may be partly caused by hypoxia introduced during and after tumour removal. Some studies suggest that hypoxia may induce both COX-2 and 5-LO expression.

Although glucocorticoids, used to treat peritumorous brain oedema, may reduce the effectiveness of chemotherapy and radiotherapy, COX-2 inhibitors may in fact enhance these treatments, and combination trials with patients with brain tumours are currently in progress. Further investigations are needed to establish whether COX-2 and 5-LO inhibitors can reduce peritumorous brain oedema in patients with brain tumours as effectively as glucocorticoids, but with less side effects. Selective COX-2 inhibitors were until recently considered to have fewer gastrointestinal adverse effects than non-selective, non-steroidal anti-inflammatory drugs. However, this premise is debatable because flaws in trial design and reporting of results cast doubts on the gastrointestinal, cardiovascular, and global safety profile of COX-2 specific inhibitors. Nevertheless, if effective for oedema reduction, these inhibitors will probably have fewer side effects than glucocorticoids. It remains to be determined whether the use of a combination of COX-2 and 5-LO inhibitors would be more effective than the use of either drug alone.

www.molpath.com
CONCLUSIONS

A new era of targeted treatments is rapidly evolving. The accrual of knowledge relating to the molecular pathways that govern the fundamental mechanisms of cell growth and survival, and how these pathways are altered in cancer, may be the key to improving patient survival and outcome from cancer in general, and particularly for patients with malignant gliomas. The downregulation or inhibition of tumour promoting eicosanoid cascades may represent one additional method of effectively and safely preventing and treating human brain tumours.

ACKNOWLEDGEMENTS

The authors would like to thank Ms M Tobin (Department of Neurosurgery) for helping to edit this manuscript.

Authors’ affiliations

N Nathoo, G H Barnett, Brain Tumour Institute and Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, 44195 Ohio, USA
M Golubic, Brain Tumor Institute, Cleveland Clinic Foundation

REFERENCES


www.molpath.com
65a
www.molpath.com
74
Simmet T
Castelli MG
69
Ohd JF
66
64
61
Ermert L
Prayson RA
60
Buckman SY
50
Cooper C
47


Downloaded from http://jcp.bmj.com/ on May 1, 2017 - Published by group.bmj.com
Nathoo, Barnett, Golubic
www.molpath.com
The eicosanoid cascade in glioma and meningioma


The eicosanoid cascade: possible role in gliomas and meningiomas

N Nathoo, G H Barnett and M Golubic

doi: 10.1136/jcp.57.1.6

Updated information and services can be found at:
http://jcp.bmj.com/content/57/1/6

These include:

References
This article cites 123 articles, 47 of which you can access for free at:
http://jcp.bmj.com/content/57/1/6#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/